Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Liwei Deng, Yan-Yuan Sun, Haiqing Wang, Changli Liao, Deshan Li, Guohui Xu, Xuegang YangJournal of Hepatocellular Carcinoma 2024 · DOI

Abstract

In comparison with TACE plus donafenib, TACE plus donafenib with ICIs could significantly improve DCR, PFS, and OS as a potential first-line treatment for unresectable HCC with an acceptable safety profile.
BibTeX
@article{deng2024efficacy,
  author = {Liwei Deng and Yan-Yuan Sun and Haiqing Wang and Changli Liao and Deshan Li and Guohui Xu and Xuegang Yang},
  title = {{Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis}},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2024},
  doi = {10.2147/jhc.s443779},
}

Loading related content...

Figure